Thus, our studies further confirm ERK1/2 as a potential therapeutic target to ameliorate multiple functions of the sickle red cell, including adhesion[18] and vaso-occlusion[10,18], chronic hemolysis and ischemic tissue damage[7], all of which are associated with the pathophysiology of SCD. The gene discussed is MAPK3; the disease is Schnyder corneal dystrophy.